Therapeutic Area - Orphan/Rare Diseases Solutions
The study of drug development for orphan and rare diseases is a very important, but highly specialized part of our industry. Not every bioanalytical CRO offers these services, and even those who do, don’t necessarily do it extremely well. When you get into the cell and gene therapy areas, for instance, you’re dealing with rare diseases and immuno-oncology – those types of therapies have a more specific set of needs, from helping with clinical supply kits, through the whole chain of sample management – it takes a very specific set of skillsets and levels of experience that most CROs out there just don’t have.
KCAS has the history and expertise to handle your orphan and rare disease studies
There are a number of considerations when developing an assay to monitor a class of biomarkers. KCAS has validated an assay for 20 amino acids (20-plex) that has been applied to support studies in metabolism and rare disease. KCAS is interested in increasing our suite of biomarker assays. We are happy to develop and qualify custom methods or collaborate on more general assays for rare/orphan diseases.